在患有复发性妇科恶性瘤的患者中,使用抗PD-1抑制剂重新挑战
Migang Kim1, Chi-Son Chang2, Min Chul Choi3
1Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Yonsei medical journal
|September 20, 2023
概括
在复发性妇科癌症中,免疫检查点抑制剂 (ICI) 重复挑战显示出一些反应,在重新暴露时发生的严重不良事件 (AE) 较少. 在临床试验之外的常规使用之前需要进一步的数据.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 复发性妇科癌症会给治疗带来挑战.
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗.
- 在初始治疗后重新挑战ICI是一种新兴的策略.
研究的目的:
- 为了研究免疫检查点抑制剂 (ICI) 在患有复发性妇科癌症的患者中重新挑战的治疗结果.
- 为了评估PD-1抑制剂的安全性和有效性,重新挑战.
主要方法:
- 对20名患有复发性妇科癌症的患者进行了回顾性审查,这些患者接受了PD-1抑制剂治疗.
- 从2018年1月到2022年9月在两个高等教育中心收集的数据.
- 对治疗反应,无进展生存 (PFS) 和不良事件 (AE) 的分析.
主要成果:
- 患者接受了pembrolizumab或nivolumab用于重新挑战.
- 初始ICI治疗显示完全响应 (CR) 在5%和部分响应 (PR) 在20%.
- 第二次ICI治疗导致5%的CR,10%的PR和25%的稳定疾病;PFS中位数为1.8个月.
- 没有AE复发发生在以前由于AE停止ICI的患者.
结论:
- 在复发性妇科癌症中,ICI重新挑战可以产生反应.
- 在AEs方面,重新挑战似乎比初始ICI治疗更难忍受.
- 需要进一步的研究,以建立ICI再挑战的常规临床实践.
更多相关视频
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.8K
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.3K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
554
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
554
